drugset / Trial / NCT05174650
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Phase 2
Active not recruiting
27 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NaSingle-groupOpen-labelTreatment
Summary
The study trial is a open-label, single-arm, multicenter phase II trial investigating the combined treatment of atezolizumab and derazantinib in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements
Timeline
- Start
- 2022-04-20
- Primary completion
- 2025-12
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Derazantinib | Small molecule | 300 mg | Oral |